Sehr guter Start für "Promi Big Brother": Starke 13,0 Prozent Marktanteil für den Einzug am Freitagabend in SAT.1
Unterföhring (ots) - Model Sarah Knappik erfindet den Toilettenbürsten-Trinkbecher, Panikattacke bei ...
Düsseldorf (ots) - Bereits zum 11. Mal rief die Mediadesign Hochschule Fußballclubs der 1. Bundesliga dazu ...
Lyon, France (ots/PRNewswire) - - Sanofi Pasteur works with global partners to make available unparalleled
quantities of affordable Inactivated Polio Vaccine (IPV) -
Sanofi Pasteur, the vaccines division of Sanofi , announced today its further commitment to the international community's efforts to complete polio eradication. UNICEF, the organization that procures the vaccine to meet global needs, announced it will purchase significant quantities of Inactivated Polio Vaccine (IPV) from Sanofi Pasteur and make it available based on country needs and vaccination plans. To achieve the goal of polio eradication by 2018, the World Health Organization (WHO) recommends that by end 2015, all children receive routinely at least one dose of IPV in over 120 countries that solely use Oral Polio Vaccine.
To view the Multimedia News Release, please click:
In order to support rapid and widespread adoption of IPV, Sanofi Pasteur - the world's largest producer of IPV - and the Bill & Melinda Gates Foundation have developed a joint price support mechanism, including a financial contribution from both organizations. This mechanism allows Sanofi Pasteur to offer IPV at a price of EUR0.75 per dose (approximately US$1) to 73 of the world's poorest countries. The GAVI Alliance, a global immunisation partnership, will make IPV available for inclusion in routine immunisation schedules in these countries.
This announcement underscores Sanofi Pasteur's commitment to offer unparalleled volumes of high-quality IPV across a broad range of countries and economic situations at differential prices in an unprecedented, global rollout.
Contacts: Global Media Relations: Alain Bernal, T.Original-Content von: sanofi-aventis Group, übermittelt durch news aktuell
+33-4-37-37-50-38, email@example.com. Sanofi Investor
Relations: Sébastien Martel, T. +33-1-53-77-45-45, firstname.lastname@example.org